Oric Pharmaceuticals (NASDAQ: ORIC) is viewed by a majority of covering biotechnology analysts as a compelling speculative buy, backed by a consensus of strong buy and buy recommendations. Bulls point to its robust cash runway extending into future years, innovative oncology pipeline targeting drug resistance in cancer, and upcoming clinical data readouts, though bears caution against standard clinical trial risks and developmental dilution.